MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
Activating mutations of EGFR are associated with sensitivity of non-small cell lung cancer (NSCLC ) to tyrosine kinase inhibitors (TKI). Liquid biopsy using circulating cell-free tumor DNA (cfDNA) is proposed in cases when formalin fixed paraffin embedded (FFPE) tumor tissue is not available and for...
Saved in:
| Main Authors: | V. A. Shamanin, I. V. Karpov, P. А. Gervas, N. V. Cherdyntseva, E. I. Simolina, V. V. Kozlov, S. P. Kovalenko |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2018-11-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/858 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Review of Plasma Exosomal DNA for Detecting EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
by: Mohammad Mehdi Jahani, et al.
Published: (2025-04-01) -
Profiling of driver mutations in lung adenocarcinoma patients identifies rare compound EGFR mutations sensitive to second-generation EGFR-TKIs
by: Jun Li, et al.
Published: (2024-12-01) -
Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01) -
Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker
by: Meejeong Kim, et al.
Published: (2025-04-01) -
Lung Adenocarcinoma With Initially Co‐Occurring EGFR and BRAF Double Mutation: A Case Report and Literature Review
by: Lu Wang, et al.
Published: (2025-03-01)